Edgar Filing: Piacquad David - Form 4

Form 4	v1d							
May 01, 2018	8							
FORM	1 /					OMB A	PPROVAL	
	UNITED ST			ND EXCHANGE D.C. 20549	COMMISSION	OMB Number:	3235-0287	
Check thi if no long	er					Expires:	January 31, 2005	
subject to	subject to STATEMENT OF CHANGES IN BENEFICIAL O				VNERSHIP OF	Estimated a	average	
Section 10 Form 4 or		. SECURITIES				burden hou response	•	
Form 5	Filed pursua	nt to Section 10	6(a) of the	Securities Exchan	ge Act of 1934,	16300136	0.5	
obligatior may conti	inue Section 17(a) o		•	ing Company Act of		ı		
See Instru	· · · · · · · · · · · · · · · · · · ·	30(h) of the Inv	vestment (Company Act of 19	940			
1(b).								
(Print or Type R	Responses)							
1. Name and A Piacquad Da		2. Issuer Name and Ticker or Trading Symbol		5. Relationship of Reporting Person(s) to Issuer				
		•	N INC [AI	MGN]	(Chaol	r all annliaghl	2)	
(Last)	(First) (Middl	le) 3. Date of	Earliest Tra	insaction	(Check all applicable)			
			ay/Year)		Director		6 Owner	
ONE AMGE	E 04/27/20)18		XOfficer (give titleOther (specify below) below)				
					,	iness Develop		
			ndment, Dat	e Original	6. Individual or Joint/Group Filing(Check			
		Filed(Mon	th/Day/Year)		Applicable Line) _X_ Form filed by C	One Reporting Po	erson	
THOUSAN	-				Form filed by M Person	lore than One Re	eporting	
OAKS, CA	91320-1799							
(City)	(State) (Zip)) Table	e I - Non-Do	erivative Securities Ac	equired, Disposed of	, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	ar	A. Deemed xecution Date, if ny Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securities onAcquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Securities I Beneficially (Owned I	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	(A) or Amount (D) Price	Transaction(s) (Instr. 3 and 4)			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

А

Common

Stock

04/27/2018

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

957 (1) A \$0 36,744 (2) (3) D

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Piacquad David - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisab Expiration Date (Month/Day/Year		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Nqso (Right to Buy)	\$ 177.46	04/27/2018		А	7,374	04/27/2020(4)	04/27/2028	Common Stock	7,374

Reporting Owners

Reporting Owner Name / Address	Relationships					
1	Director	10% Owner	Officer	Other		
Piacquad David ONE AMGEN CENTER DRIVE THOUSAND OAKS, CA 91320-1799			SVP, Business Development			
Signatures						
/s/ Andrea A. Robinson, Attorney-in-Fa Piacquad	act for Mi		05/01/2018			
<u>**</u> Signature of Reporting Person			Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively.

These shares include the following RSUs granted under the Company's equity plans: 357 RSUs which vest in one installment on 1/30/2019; 1,023 RSUs with vest in 3 annual installments of 337, 338 and 348 on 5/3/2018, 5/3/2019 and 5/3/2020, respectively; and 984

(2) RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

These shares include 112 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in

- (3) That and subject to a qualifying dividend reinvestnent plan. Des are credited on the reporting person's divested RSOs and are paid out shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.
- (4) These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.